511 related articles for article (PubMed ID: 18794551)
1. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens RJ; Dirix LY; Beex LV; Nooij M; Cameron DA; Cufer T; Piccart MJ; Bogaerts J; Therasse P
J Clin Oncol; 2008 Oct; 26(30):4883-90. PubMed ID: 18794551
[TBL] [Abstract][Full Text] [Related]
2. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
3. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
5. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Cufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M;
Ann Oncol; 2003 Sep; 14(9):1391-8. PubMed ID: 12954578
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
7. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
8. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Bertelli G; Hall E; Ireland E; Snowdon CF; Jassem J; Drosik K; Karnicka-Mlodkowska H; Coombes RC; Bliss JM
Ann Oncol; 2010 Mar; 21(3):498-505. PubMed ID: 19717534
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
11. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
12. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
13. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
14. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
16. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
Jones SE
Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S41-4. PubMed ID: 16595025
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
[TBL] [Abstract][Full Text] [Related]
18. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
[TBL] [Abstract][Full Text] [Related]
19. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
20. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]